apn-1607
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 19, 2019 (NCT04141150)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05542953 | Phase 3 | Feb 11, 2022 | Aprinoia Therapeutics Inc. |
| NCT05043675 | Early Phase 1 (Phase 1) | Sep 10, 2021 | Nanjing Medical University |
| NCT05005819 | Phase 1 | May 25, 2021 | Invicro |
| NCT04141150 | Phase 2 | Aug 19, 2019 | Aprinoia Therapeutics Inc., Invicro |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aprinoia Therapeutics Inc. | For profit | 2 | 2 | 2 | 2019 |
| Invicro | For profit | 2 | 1 | 2 | 2019 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1